Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining 28.8% over the past four weeks, the stock looks well positioned for a ...

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...

The landscape of drug discovery has been dramatically shifting, thanks in large part to the influence of artificial intelligence (AI).

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...

Cohesity, the leader in AI-powered data security, today announced it is the first data protection provider to achieve Nutanix Database Service (NDB) database protection Nutanix Ready validation.